MedTrace Logo

Side Effects of Atropine (SEA) Study

NCT03593044 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-12-02

Study results available
· View outcomes & findings →

Summary

This study will perform several objective and subjective measurements of the eye and vision before and after a week of using 0.01% concentration atropine drops. These measurements will help to obtain a comprehensive understanding of the side effects of this concentration of atropine and determine if the drops would be tolerated as a possible preventative treatment for nearsightedness.

Conditions

  • Myopia

Interventions

DRUG

0.01% concentration atropine drops

One drop of 0.01% concentration atropine in each eye at night for seven days.

Sponsors & Collaborators

  • Jeffrey J. Walline, OD PhD

    lead OTHER

Principal Investigators

  • Jeffrey Walline · Ohio State University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-23
Primary Completion
2019-01-17
Completion
2019-01-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03593044 on ClinicalTrials.gov